GSK 0001654954-26-003598 6-K Filing: Apr 16, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Luke Miels
b)	Position/status	Chief Executive Officer
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 April 2026 on<br>Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£21.6700	232
			£21.6700	630
			£21.6700	316

d)	Aggregated<br>information
	Aggregated<br>volume<br><br><br><br><br><br>Price	1,178<br><br> <br><br><br>21.6700
e)	Date<br>of the transaction	2026-04-14
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Julie Brown
b)	Position/status	Chief Financial Officer
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 April 2026 on<br>Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£21.6700	458
			£21.6700	589
			£21.6700	506

d)	Aggregated<br>information
	Aggregated<br>volume<br><br><br><br><br><br>Price	1,553<br><br><br><br><br> <br><br><br>21.6700
e)	Date<br>of the transaction	2026-04-14
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Diana Conrad
b)	Position/status	Chief People Officer
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 April 2026 on<br>Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£21.6700	132
			£21.6700	132
			£21.6700	334

d)	Aggregated<br>information
	Aggregated<br>volume<br><br><br><br><br><br>Price	598<br><br> <br><br><br>21.6700
e)	Date<br>of the transaction	2026-04-14
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 April 2026 on<br>Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£21.6700	109
			£21.6700	339
			£21.6700	205

d)	Aggregated<br>information
	Aggregated<br>volume<br><br><br><br><br><br>Price	653<br><br> <br><br><br>21.6700
e)	Date<br>of the transaction	2026-04-14
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Shobie Ramakrishnan
b)	Position/status	Chief Digital and Technology Officer
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	American Depositary Shares ('ADS')<br><br><br> <br><br><br>ISIN: US37733W2044
b)	Nature<br>of the transaction	Increase in notional interest in ADS following the re-investment of<br>dividends paid to shareholders on 9 April 2026 on ADSs held in the<br>Company's Deferred Annual Bonus Plan
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			$58.3600	53
			$58.3600	96
			$58.3600	159

d)	Aggregated<br>information
	Aggregated<br>volume<br><br><br><br><br><br>Price	308<br><br> <br><br><br>58.3600
e)	Date<br>of the transaction	2026-04-14
f)	Place<br>of the transaction	New York Stock Exchange (XNYS)

All values are in US Dollars.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 April 2026 on<br>Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£21.6700	161
			£21.6700	401
			£21.6700	183

d)	Aggregated<br>information
	Aggregated<br>volume<br><br><br><br><br><br>Price	745<br><br> <br><br><br>21.6700
e)	Date<br>of the transaction	2026-04-14
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 April 2026 on<br>Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£21.6700	169
			£21.6700	483
			£21.6700	268

d)	Aggregated<br>information
	Aggregated<br>volume<br><br><br><br><br><br>Price	920<br><br> <br><br><br>21.6700
e)	Date<br>of the transaction	2026-04-14
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Philip Thomson
b)	Position/status	President, Global Affairs
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 April 2026 on<br>Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£21.6700	117
			£21.6700	163
			£21.6700	270

d)	Aggregated<br>information
	Aggregated<br>volume<br><br><br><br><br><br>Price	550<br><br> <br><br><br>21.6700
e)	Date<br>of the transaction	2026-04-14
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 April 2026 on<br>Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£21.6700	154
			£21.6700	418
			£21.6700	252

d)	Aggregated<br>information
	Aggregated<br>volume<br><br><br><br><br><br>Price	824<br><br> <br><br><br>21.6700
e)	Date<br>of the transaction	2026-04-14
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Tony Wood
b)	Position/status	Chief Scientific Officer
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br> <br><br><br>ISIN: GB00BN7SWP63
b)	Nature<br>of the transaction	Increase in notional interest in Ordinary Shares following the<br>re-investment of dividends paid to shareholders on 9 April 2026 on<br>Ordinary Shares held in the Company's Deferred Annual Bonus<br>Plan
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			£21.6700	215
			£21.6700	235
			£21.6700	515

d)	Aggregated<br>information
	Aggregated<br>volume<br><br><br><br><br><br>Price	965<br><br> <br><br><br>21.6700
e)	Date<br>of the transaction	2026-04-14
f)	Place<br>of the transaction	London Stock Exchange (XLON)

All values are in British Pounds.

1.	Details of PDMR/person closely associated with them<br>('PCA')
a)	Name	Elizabeth McKee Anderson
b)	Position/status	Independent Non-Executive Director
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	American Depositary Shares ('ADS')<br><br><br><br><br><br>ISIN: US37733W2044
b)	Nature<br>of the transaction	Acquisition of ADS following the re-investment of dividends paid to<br>shareholders on 9 April 2026
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			$58.9307	26

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume<br><br><br><br><br><br>Price
e)	Date<br>of the transaction	2026-04-09
f)	Place<br>of the transaction	New York Stock Exchange (XNYS)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	Charles Bancroft
b)	Position/status	Senior Independent Non-Executive Director
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	American Depositary Shares ('ADS')<br><br><br><br><br><br>ISIN: US37733W2044
b)	Nature<br>of the transaction	Acquisition of ADS following the re-investment of dividends paid to<br>shareholders on 9 April 2026
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			$58.9307	313

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume<br><br><br><br><br><br>Price
e)	Date<br>of the transaction	2026-04-09
f)	Place<br>of the transaction	New York Stock Exchange (XNYS)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	Dr Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	American Depositary Shares ('ADS')<br><br><br><br><br><br>ISIN: US37733W2044
b)	Nature<br>of the transaction	Acquisition of ADS following the re-investment of dividends paid to<br>shareholders on 9 April 2026
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			$58.9307	26

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume<br><br><br><br><br><br>Price
e)	Date<br>of the transaction	2026-04-09
f)	Place<br>of the transaction	New York Stock Exchange (XNYS)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	Dr Anne Beal
b)	Position/status	Independent Non-Executive Director
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	American Depositary Shares ('ADS')<br><br><br><br><br><br>ISIN: US37733W2044
b)	Nature<br>of the transaction	Acquisition of ADS following the re-investment of dividends paid to<br>shareholders on 9 April 2026
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			$58.9307	32

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume<br><br><br><br><br><br>Price
e)	Date<br>of the transaction	2026-04-09
f)	Place<br>of the transaction	New York Stock Exchange (XNYS)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	Dr Harry Dietz
b)	Position/status	Independent Non-Executive Director
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneeror auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	American Depositary Shares ('ADS')<br><br><br><br><br><br>ISIN: US37733W2044
b)	Nature<br>of the transaction	Acquisition of ADSs following the re-investment of dividends paid<br>to shareholders on 9 April 2026
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			$58.9307	30

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume<br><br><br><br><br><br>Price
e)	Date<br>of the transaction	2026-04-09
f)	Place<br>of the transaction	New York Stock Exchange (XNYS)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	Dr Jeannie Lee
b)	Position/status	Independent Non-Executive Director
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	American Depositary Shares ('ADS')<br><br><br><br><br><br>ISIN: US37733W2044
b)	Nature<br>of the transaction	Acquisition of ADSs following the re-investment of dividends paid<br>to shareholders on 9 April 2026
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			$58.9307	14

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume<br><br><br><br><br><br>Price
e)	Date<br>of the transaction	2026-04-09
f)	Place<br>of the transaction	New York Stock Exchange (XNYS)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	Dr Vishal Sikka
b)	Position/status	Independent Non-Executive Director
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	American Depositary Shares ('ADS')<br><br><br><br><br><br>ISIN: US37733W2044
b)	Nature<br>of the transaction	Acquisition of ADSs following the re-investment of dividends paid<br>to shareholders on 9 April 2026
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			$58.9307	96

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume<br><br><br><br><br><br>Price
e)	Date<br>of the transaction	2026-04-09
f)	Place<br>of the transaction	New York Stock Exchange (XNYS)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	American Depositary Shares ('ADS')<br><br><br><br><br><br>ISIN: US37733W2044
b)	Nature<br>of the transaction	Acquisition of ADS following the re-investment of dividends paid to<br>shareholders on 9 April 2026
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			$59.1703	270.573

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume<br><br><br><br><br><br>Price
e)	Date<br>of the transaction	2026-04-14
f)	Place<br>of the transaction	New York Stock Exchange (XNYS)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	Maya Martinez-Davis
b)	Position/status	President, US
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	American Depositary Shares ('ADS')<br><br><br><br><br><br>ISIN: US37733W2044
b)	Nature<br>of the transaction	Acquisition of ADS following the re-investment of dividends paid to<br>shareholders on 9 April 2026
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			$59.1703	292.894

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume<br><br><br><br><br><br>Price
e)	Date<br>of the transaction	2026-04-14
f)	Place<br>of the transaction	New York Stock Exchange (XNYS)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	Maya Martinez-Davis
b)	Position/status	President, US
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	American Depositary Shares ('ADS')<br><br><br><br><br><br>ISIN: US37733W2044
b)	Nature<br>of the transaction	Acquisition of ADS following the re-investment of dividends paid to<br>shareholders on 9 April 2026
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			$58.3600	151.897


d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume<br><br><br><br><br><br>Price
e)	Date<br>of the transaction	2026-04-14
f)	Place<br>of the transaction	New York Stock Exchange (XNYS)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	Shobie Ramakrishnan
b)	Position/status	Chief Digital and Technology Officer
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	American Depositary Shares ('ADS')<br><br><br><br><br><br>ISIN: US37733W2044
b)	Nature<br>of the transaction	Acquisition of ADS following the re-investment of dividends paid to<br>shareholders on 9 April 2026
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			$59.1703	600.819

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume<br><br><br><br><br><br>Price
e)	Date<br>of the transaction	2026-04-14
f)	Place<br>of the transaction	New York Stock Exchange (XNYS)
1.	Details of PDMR/person closely associated with them<br>('PCA')
---	---	---	---	---	---
a)	Name	Diana Conrad
b)	Position/status	Chief People Officer
c)	Initial<br>notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted
a)	Description<br>of the financial instrument	American Depositary Shares ('ADS')<br><br><br><br><br><br>ISIN: US37733W2044
b)	Nature<br>of the transaction	Acquisition of ADS under GSK pension plan
c)	Price(s)<br>and volume(s)		Price(s)	Volume(s)
			$58.3499	11.357

d)	Aggregated<br>information	N/A (single transaction)
	Aggregated<br>volume<br><br><br><br><br><br>Price
e)	Date<br>of the transaction	2026-04-13
f)	Place<br>of the transaction	New York Stock Exchange (XNYS)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

	GSK plc
	(Registrant)

Date: April<br>16, 2026

	By:/s/ VICTORIA<br>WHYTE<br><br><br>--------------------------

	Victoria Whyte
	Authorised<br>Signatory for and on
	behalf<br>of GSK plc

GSK 6-K